Meta-analytic correspondence reveals robust efficacy across pooled prasugrel doses in acute coronary syndrome, supporting flexible antiplatelet evaluation strategies.
Key Points
To address methodological considerations and justify the strategy of pooling variable prasugrel dosing regimens within a P2Y12 inhibitor network meta-analysis.
Assessed methodological concerns raised regarding the pooling of different prasugrel doses across randomized clinical trials.
Evaluated network meta-analysis model assumptions and treatment comparability across clinical trial arms.
Clarified that pooling prasugrel doses maintains consistent relative risk estimates compared with other P2Y12 inhibitors.
Affirmed that network meta-analysis sensitivity analyses support the primary cardiovascular and bleeding outcome conclusions.